Cancer variation associated with the position of the mutation in the BRCA2 gene

Familial Cancer

Volumn 3, Issue 1, 2004, Pages 1-10

  Lubinski, Jan ^a   Phelan, Catherine M ^b   Ghadirian, Parviz ^c   Lynch, Henry T ^d   Garber, Judy ^e   Weber, Barbara ^f   Tung, Nadine ^g   Horsman, Douglas ^h   Isaacs, Claudine ⁱ   Monteiro, Alvaro N A ^j   Sun, Ping ^b   Narod, Steven A ^b  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Centre for Research on Women's Health   (Canada)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d CREIGHTON UNIVERSITY   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF PENNSYLVANIA   (United States)

^g BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^h BRITISH COLUMBIA CANCER AGENCY   (Canada)

ⁱ GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^j WEILL CORNELL MEDICAL COLLEGE   (United States)

more..

Author keywords

BRCA2; Cancer risk; Phenotypic variation

Indexed keywords

BRCA2 PROTEIN;

ARTICLE; BREAST CARCINOMA; CANCER RISK; CLUSTER ANALYSIS; COLON CARCINOMA; CONTROLLED STUDY; DISEASE ASSOCIATION; ETHNOLOGY; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC VARIABILITY; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; ONCOGENE; OVARY CARCINOMA; PANCREAS CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; REDUCTION; STOMACH CARCINOMA; BREAST TUMOR; COHORT ANALYSIS; COLON TUMOR; COMPARATIVE STUDY; GENETIC PREDISPOSITION; GENETICS; HETEROZYGOTE; MUTATION; NEOPLASM; OVARY TUMOR; PANCREAS TUMOR; PATHOLOGY; PEDIGREE; PROSTATE TUMOR; RISK; STOMACH TUMOR; TUMOR SUPPRESSOR GENE;

BRCA2 PROTEIN; BREAST NEOPLASMS, MALE; CLUSTER ANALYSIS; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HETEROZYGOTE; HUMANS; MALE; MELANOMA; MUTATION; NEOPLASMS; ODDS RATIO; OVARIAN NEOPLASMS; PANCREATIC NEOPLASMS; PEDIGREE; PHENOTYPE; PROSTATIC NEOPLASMS; STOMACH NEOPLASMS; VARIATION (GENETICS);

EID: 3142730982     PISSN: 13899600     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:FAME.0000026816.32400.45     Document Type: Article

References (32)

1. Wooster R, Neuhausen S, Mangion J et al. Localisation of a breast cancer susceptibility gene (BRCA2) to chromosome 13q by genetic linkage analysis. Science 1994; 265: 2088-90.
2. Wooster R, Bignell G, Swift S et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378: 789-92.
3. Tavtigian SV, Simard J, Rommens J et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12: 333-7.
4. BCLC - The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1991; 91: 1310-6.
5. Risch HA, McLaughlin JR, Cole DE et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet 2001; 68: 700-10.
6. Gayther SA, Mangion J, Russell P et al. Variation of risks of breast and ovarian cancer associated with different germline mutations of the BRCA2 gene. Nat Genet 1997; 15: 103-5.
7. Thompson D, Easton D. Breast Cancer Linkage Consortium. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001; 68: 410-9.
8. Narod SA, Risch H, Moslehi R et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339: 424-8.
9. Narod SA, Dube M-P, Klijn J et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94: 1773-9.
10. Parkin DM, Whelan SL, Ferlay J et al. Cancer Incidence in Five Continents. Lyon: IARC Press, 1997.
11. Jakubowska A, Nej K, Huzarski T et al. BRCA2 gene mutations in families with aggregations of breast and stomach cancers. Br J Cancer 2002; 87: 888-91.
12. Phelan CM, Lancaster JM, Tonin P et al. Mutation analysis of the BRCA2 gene in 49 site-specific breast cancer families. Nat Genet 1996; 13: 120-2.
13. Moslehi R, Chu W, Karlan B et al. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer. Am J Hum Genet 2000; 66: 1259-72.
14. Sinilnikova OM, Egan KM, Quinn JL et al. Germline BRCA2 sequence variants in patients with ocular melanoma. Int J Cancer 1999; 82: 325-8.
15. Iscovich J, Abdulrazik M, Cour C et al. Prevalence of the BRCA2 6174delT mutation in Israeli uveal melanoma patients. Int J Cancer 2002; 98: 42-4.
16. Scully R, Livingston D. In search of the tumour-suppressor functions of BRCA1 and BRCA2. Nature 2000; 408: 429-32.
17. Venkitaraman AR. Cancer Susceptibility and the Functions of BRCA1 and BRCA2. Cell 2002; 108: 171-82.
18. Moynahan ME, Pierce AJ, Jasin M. BRCA2 is required for homology-directed repair of chromosomal breaks. Mol Cell 2001; 7: 263-72.
19. Bork P, Blomberg N, Nilges M. Internal repeats in the BRCA2 protein sequence. Nat Genet 1996; 13: 22-3.
20. Chen PL, Chen CF, Chen YM et al. The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methane-sulfonate treatment. Proc Natl Acad Sci USA 1998; 95: 5287-92.
21. Katagiri T, Saito H, Shinohara A et al. Multiple possible sites of BRCA2 interacting with DNA repair protein RAD51. Genes Chromosomes Cancer 1998; 21: 217-22.
22. Chen CF, Chen PL, Zhong Q et al. Expression of BRC repeats in breast cancer cells disrupts the BRCA2-Rad51 complex and leads to radiation hypersentsityivy and loss of G(2)/M checkpoint control. J Biol Chem 1999; 274: 32931-5.
23. Davies AA, Masson JY, McIlwraith MJ et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell 2001; 7: 273-82.
24. Xia F, Taghian DG, DeFrank JS et al. Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining. Proc Natl Acad Sci USA 2001; 98: 8644-9.
25. Stark JM, Hu P, Pierce AJ et al. ATP hydrolysis by mammalian RAD51 has a key role during homology-directed DNA repair. J Biol Chem 2002; 277: 20185-94.
26. Yang HJ, Jeffrey PD, Miller J et al. BRCA2 function in DNA binding and recombination from a BRCA2-DSS1-ssDNA structure. Science 2002; 297: 1837-48.
27. Marston NJ, Richards WJ, Hughes D et al. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol 1999; 19: 4633-42.
28. Spain BH, Larson CJ, Shihabuddin LS et al. Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations. Proc Natl Acad Sci USA 1999; 96: 13920-5.
29. Hewlett NG, Taniguchi T, Olson S et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science 2002; 297: 606-9.
30. Mazoyer S, Dunning AM, Serova O et al. A polymorphic stop codon in BRCA2. Nat Genet 1996; 14: 253-4.
31. Zhang J, Sun XL, Qian YM et al. At least one intron is required for the nonsense-mediated decay of triosephosphate isomerase mRNA: A possible link between nuclear splicing and cytoplasmic translation. Mol Cell Biol 2002; 18: 5272-83.
32. Perrin-Vidoz L, Sinilnikova OM, Stoppa-Lyonet D et al. The non-sense mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature stop codons. Hum Mol Genet 2002; 11: 2805-14.